EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)

Category Primary study
JournalEUROPEAN JOURNAL OF CANCER
Year 2014
This article has no abstract
Epistemonikos ID: 21f510e2b66c07d5c26fc68847d89f0deae34e86
First added on: Feb 06, 2025